TPCA-1 is primarily used in research settings as a selective inhibitor of IKK-2, an enzyme involved in the NF-κB signaling pathway. This pathway plays a critical role in regulating immune responses, inflammation, and cell survival. By inhibiting IKK-2, TPCA-1 helps researchers study the effects of blocking NF-κB activation in various cellular processes. It is particularly useful in understanding inflammatory diseases, such as rheumatoid arthritis, asthma, and other conditions where NF-κB signaling is dysregulated. Additionally, TPCA-1 is employed in cancer research to investigate the role of NF-κB in tumor growth and resistance to therapy. Its application provides valuable insights into potential therapeutic targets for treating inflammation-related disorders and cancer.